Loading…
BCDA
BioCardia, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 09060U606
$1.15-1.71%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $17.41M
- P/E
- —
- Forward P/E
- —
- P/B
- 6.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.59
- ROE
- -1803.19%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.49
- 52-week high
- $2.29
- 52-week low
- $0.75
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -97.5% over 5Y.
today you would have $22.29▼ -97.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.25 | $2.18 | $9.90 | $31.35 | $29.10 | $51.90 | $55.20 | $162.00 | $317.25 | $1,749.60 | $129.60 | $178.20 | $129.60 | $97.20 | $113.40 | $81.00 | |
| P/E | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TPSTTempest Therapeutics, Inc. | $1.06 | — | 18.6x | — | -931.14% | $17.53M |
| LEXXLexaria Bioscience Corp. | $10.35 | — | 3.6x | — | -162.77% | $17.1M |
| LPCNLipocine Inc. | $2.17 | — | 0.8x | — | -60.94% | $17.89M |
| HKPDCellyan Biotechnology Co., Ltd | $0.35 |
About the company
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
- 17
- Sunnyvale, United States
Company description provided by Yahoo Finance.